Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions

Similar documents
The patient with multiple chronic conditions: balancing guidelines and patient preference

MEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

The Latest Generation of Clinical

Practical Use of Decision Aids in Primary Care. Michael Soung, MD, FACP Virginia Mason Medical Center General Internal Medicine

Predicting and changing the future for people with CKD

STOPP and START criteria October 2011

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION

A Guidance Statement from the American College of Physicians

Prevention: When Do Benefits Start and End? What Do They Have in Common?

Geriatric Grand Rounds

Romayne Gallagher MD, CCFP Divisions of Residential and Palliative Care Providence Health Care Vancouver, BC

Finding the sweet spot: Individualized targets for older adults with Type 2 DM

Polypharmacy & De-prescribing In Older Adults

Difficult to Treat Hypertension

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Women and Vascular Disease

Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Preventing and Treating High Blood Pressure

Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists

Modern Management of Hypertension

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

Polypharmacy, Medication Nihilism, and the art of de-prescribing

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Summary of 2012/13 QOF Changes

Murthy Gokula MD,CMD

STOPP START Toolkit Supporting Medication Review in the Older Person

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director

Primary Care Pharmacist Integration and Reimbursement Models

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

egfr > 50 (n = 13,916)

Integrating Goals of Care Discussions into Routine Care

Patient-centered Care and Multimorbidity. Journal Club Christina Rincón, MD December 6, 2012

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

Preoperative Cardiac Evaluation:

ADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT?

Modern Management of Hypertension: Where Do We Draw the Line?

Presenter Disclosure

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

COMPARATIVE EFFECTIVENESS REVIEWS FOR CLINICIANS: Helping us Make Better Treatment Decisions. Research Focus: 14 Priority Conditions

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Coronary Heart Disease in Women Go Red for Women

Ambulatory Rotation Mini-lecture Curriculum for IM Residents

Faculty/Presenter Disclosure

Should Care Be Patient- Centered or Guideline Oriented?

Hypertension in the very old. Objectives: Clinical Perspective

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI,

Managing Chronic Kidney Disease: Reducing Risk for CKD Progression

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Hypertension Management Controversies in the Elderly Patient

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

Informed Consent, Goals and Targets

JAMA. 2011;305(24): Nora A. Kalagi, MSc

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio

MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE

Best Practices in Managing Patients with Heart Failure Collaborative

Clinical Controversies in Perioperative Medicine

Analyzing Clusters of Disease and Populations to Simplify and Improve Care Delivery. July 28, 2016

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

BLCS 1-Clinical Overview. Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative

Supplementary material

MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT?

Confidence Scale. Comparative Effectiveness Reviews for Clinicians

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Rationalizing Medications. Tan Jianming Senior Pharmacist KTPH

Update in Hypertension

Screening tools for elderly patients in primary care

Clinical Controversies in Perioperative Medicine

Treating Hypertension in 2018: What Makes the Most Sense Today?

Medical Apps for Cardiology Uses. There s an App for That!

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Update in Outpatient Medicine ACP Scientific Session November 12, 2016

Preoperative Evaluation Guidelines and Work up

To fully participate in this session: Please obtain a Framingham Risk Calculator google: My Health Alberta Risk Calculator click: Heart Disease Risk

Best Practices in Cardiac Care: Getting with the Guidelines

Diabetes and the Heart

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

SESSION 3 11 AM 12:30 PM

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Early Intervention the Key to Geriatric Assessment: Geriatric Assessment Outreach Teams

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Hypertension (JNC-8)

Medically Complex Older Adults: The Pharmacotherapeutic Challenge

Geriatric Pharmacology

Update in the Literature 2012

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

Objectives. Case Ruby. 1- Warfarin. 1- Warfarin. Warfarin discontinuation 8/13/ DRUGS TO STOP GIVING HOSPICE PATIENTS

Reducing Hospital Readmissions and Increasing Time to Hospital Readmission in Blacks with Heart Failure

Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis

Heart Disease in Women: Is it Really Different?

Polypharmacy. A CPPE distance learning programme

Transcription:

Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions Mary Tinetti, M.D. Canadian Geriatrics Society May, 2013

CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure Faculty: Mary Tinetti Relationships with commercial interests: Grants/Research Support: National Institutes of Health Speakers Bureau/Honoraria: None Consulting Fees: None Other: None

CFPC CoI Templates: Slide 2 Disclosure of Commercial Support This program has received financial support from: None This program has received in-kind support from: None Potential for conflict(s) of interest: None

CFPC CoI Templates: Slide 3 Mitigating Potential Bias Not applicable

Objectives To discuss limitations of current diseaseoutcome driven decision-making for persons with MCC To describe a health outcome priority driven approach to decision-making for persons with MCC

Why important: MCC common 3/4 persons 65 y.o. have multiple conditions 1/4 adults < 65 y.o. who receive health care have multiple conditions Most healthcare for persons with MCC MCC is the NORM Anderson G; Fortin M; others

Why important: Problem with diseaseoutcome focus in face of MCC Causes treatment burden, complexity Causes therapeutic competition: Ø Treatment of one condition worsens another condition Ignores inherent tradeoffs Ignores individuals health outcome priorities

Problem with disease-outcome focus with MCC: Treatment burden and complexity 9 Conditions studied: Ø AF,HF, angina, HTN, Hyperlipidemia, DM, COPD, osteoporosis, osteoarthritis Boyd et al, JAMA 2005

Treatment Regimen Based on Clinical Practice Guidelines for a 79-Year-Old Woman With Hypertension, Diabetes Mellitus, Osteoporosis, Osteoarthritis, and COPD* Boyd, C. M. et al. JAMA 2005;294:716-724. Copyright restrictions may apply."

Problem with disease-outcome focus with MCC: Therapeutic competition Medication treating one condition may worsen coexisting condition Undetected therapeutic competition may be widespread Ø Disease guidelines recommend multiple drugs Ø People have multiple conditions

Prevalence of potential therapeutic competition in older adults Aim: Identify common chronic conditions and medications involved in potential therapeutic competition Participants: Nationally representative sample of 6,844 older adults in U.S. Lorgunpai S, Tinetti M, et al (submitted)

Chronic condi:ons: Prevalence >5%* Hypertension (72%) Hyperlipidemia (60%) Osteoarthri:s (52%) DM 2 (28%) CAD (27%) COPD (18%) GERD/PUD (17%) Hypothyroidism (15%) Atrial fibrilla:on (13%) Heart failure (13%) Osteoporosis (11%) BPH (11%) Depression (7%) Demen:a (6%) 1+ medica:on recommended

Medica:ons 26 medication classes recommended by national disease guidelines for these 14 chronic conditions Data sources for potential therapeutic competition: Disease guidelines; 2+ studies in medical literature since 2000

Examples of potential therapeutic competition Coexisting Conditions Hypertension & COPD Diabetes & Heart Failure No. Particip. Pop. Estimates 1052 3812031 % Receiving Potentially Competing Med Nonselective β-blocker (6%) Αβ-blocker (9%) Beta-agonist (38%) 405 1420958 Glitazone (13%) Osteoporosis & GERD/PUD 248 906295 Proton pump inhib. (63%) Bisphosphonate (43%)

Prevalence of potential therapeutic competition % of Par(cipants 40% 35% 30% 25% 20% 15% 10% 5% 0% 36% 20% 12% 1 med 2 meds 3 meds

Problem with disease-outcome focus with MCC: Ignore tradeoffs and priorities

Tradeoff in persons with coexisting HTN and fall risk ~1/3 persons 70 y.0. have both With antihypertensive medications: Ø Absolute 5-year risk of CV (stroke or MI) event 26% to 18% but Ø Absolute risk of serious fall injury 18% to 24% and symptoms in ~20%

Variable priorities in persons with coexisting HTN and fall risk 125 persons 70 y.o. presented trade off: CV outcomes vs. fall injury / medication symptoms Tinetti et al, J Am Geriatr Soc, 2008

Variable priorities in persons with coexisting HTN and fall risk Findings: Ø 1/2 prioritize avoiding CV events over fall injury or medication symptoms Ø 1/2 prioritize avoiding fall injury or medication symptoms over CV events Tinetti et al, J Am Geriatr Soc, 2008

What do you think?

1º care MDs perceptions of caring for older adults with multiple conditions Asked 5 focus groups of community and faculty practices (N~50) about Issues complicating decision-making for patients with multiple conditions Fried T, Tinetti M, Arch Int Med 2011

Tradeoffs between conditions Even if I know that there is a benefit to x in hypertension or y in diabetes, [what is] the relative benefit when there are multiple of them? So this patient today, would it be better to treat their depression than to get their A1C down?

Lack of data for outcomes important to patients They [trials] are looking at mortality and don t take into consideration the patient s perspective on the benefits that they would hope to receive. the problem of the outcome is that the lack of pain is probably as important an outcome as saving her life.

So is there a better way?

Is there a better way? Problem: Single disease-outcome focus in decision-making for patients with multiple chronic conditions Possible solution: Universal outcomes in decision-making for patients with multiple chronic conditions

Universal, cross-disease outcomes Key Characteristics Ø Meaningful to patients Ø ALL diseases exert their effect Ø Individuals able to prioritize Potential Uses: Ø Make treatment decisions (practice) Ø Common metric to determine benefits and harms (research)

Meaningful to patients

Views of older persons with multiple conditions on competing outcomes Methods Ø 66 persons 65 y.o. taking 5 medications Ø Qualitative; participants asked goals of treatment Results Ø Initially discussed disease-specific outcomes (e.g. BP, lipid level) Ø Shifted from disease-specific to universal, cross-disease health outcomes Fried TR, et al, JAGS 2008

Treatment goals generated by participants Desired outcomes Extend life Preserve Ø physical function Ø social function Prevent worsening of conditions Improve symptoms Ø Pain, SOB, depression Undesired Outcomes Extend life w.o quality Symptoms Ø Pain; Nausea; Drowsiness; Dizziness Mental slowing, fogginess Fried TR, et al, JAGS 2008

Universal health outcomes as way to elicit priorities. Is it most important to patient.. To be as functional as possible (physical, cognitive, social) As free of symptoms as possible (e.g. dyspnea, pain, fatigue) Live as long as possible?

Do chronic conditions exert their effect on universal health outcomes?

Determine relative effect of five chronic conditions on universal outcomes Participants: 5298 community-living individuals 65 y.o. Chronic conditions: Heart failure, COPD, osteoarthritis; depression, dementia Outcomes: Self-rated health; ADL function; symptom burden, survival

Independent effect of each condition on function (no. ADL difficulties) Chronic Condition Beta (SE)* P-Value Heart failure.70 (.08) <.001 COPD.28 (.05) <.001 Arthritis.27 (.03) <.001 Depression.59 (.04) <.001 Dementia.58 (.06) <.001 *Difference in number of ADL difficulties (range 1-12) in those with vs. w.o. condition; adj. for other conditions, covariates

Independent effect of each condition on No. of symptoms Chronic Condition Beta (SE)* P-Value Heart failure.40 (.08) <.001 COPD.40 (.05) <.001 Arthritis.57 (.03) <.001 Depression 1.18 (.04) <.001 Dementia -.08 (.06).18 *Difference in No. symptoms (pain, fatigue, SOB, dizziness, weakness, GI) in those with vs. w.o. condition; adj. for other conditions and covariates

Independent association between conditions and death within 2 years Chronic condition Hazard ratio (95% CI)* Heart failure 2.8 (2.0-4.1) COPD 2.6 (1.9-3.5) Arthritis 0.9 (0.7-1.1) Depression 1.5 (1.1-2.0) Dementia 2.1 (1.5-2.9) * Risk of dying in those with vs. w.o. the condition; adj. for other conditions and covariates

Can individuals prioritize among outcomes when there is a tradeoff? Participants: 337 older adults from senior centers and 1 independent living facility Method Ø Script explaining concept of competing outcomes (tradeoffs) Ø Rank ordered priorities. Ø Priority on visual analog scale (0-100) Fried TR, et al. Arch Int Med, 2011

Computerized Outcome Priority Scale (Fried TR; Arch Intern Med, 2011)

Most important outcome among older adults with multiple conditions when faced with tradeoff Varied in their outcome priority Ø Maintain function: 76% Ø Relief of pain or other symptoms: 13% Ø Keep alive: 11% Fried TR, et al; Arch Intern Med, 2011 Priorities across 3 studies: Function 42%; Symptom burden 32%; Keep alive 27%

Health outcomes meaningful to older adults with multiple conditions Patients with MCC think in terms of general, not disease-specific outcomes Understand the concept of tradeoffs among outcomes Agree on a small set of meaningful outcomes Able to articulate priorities in face of tradeoffs Fried TR, Arch Intern Med, 2011; Patient Educ Couns, 2010; J Am Geriatr Soc, 2008

Outcome priority decision-making with MCC Ascertain a patient s health outcome priorities; Calculate likely effect of treatment options on these health outcome priorities; Shared decision-making informed by this information.

Mrs. S (81 y.o. with fatigue, weakness, no appetite) DM HTN; CAD CKD Atrial fibrillation Depression Cataracts Osteoporosis GERD

Mrs. S: Medications (N=16) coumadin ACEI furosemide KCL statin sulfonurea metformin beta blocker SSRI bisphosphonate Calcium Vitamin D proton pump inhibitor aspirin

Clinical decision-making Disease-outcome care: Diagnose, prevent, or treat individual diseases Patient-outcome priority care: Maximize patient- specific priorities within context of patient-specific health conditions and risks

Disease outcome(s) BP control HgA1C control Avoid MI Avoid stroke Avoid fracture Avoid HF rehospitalization Avoid ESRD Avoid GI bleed Better depression score

If follow guideline for each disease and β-blocker: More fatigued if β- Blocker and coumadin: chance of GI bleed because of GERD Add bisphosphonate: worsen GERD, appetite Add insulin: treatment more complex, chance of low blood sugar Add 2 nd antidepressant: More fatigue

Patient-outcome decision-making for Mrs. S Ascertain her outcome priorities and goals Ø Fewer symptoms and better function Treatment recommendations based on meeting those goals Ø Reduce or stop β-blockers, bisphosphonate,?stain, Ø Support participation in meals, exercise, and social programs

Arguments against patient-outcome priority care and decision-making l l l Chaos (everyone with different outcome ( priorities Patients (and clinicians) will not understand priorities / tradeoffs rather than interindividual variations

There are barriers and challenges